OSE2101 + Pembrolizumab 25 MG/ML [Keytruda]
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-sensitive Ovarian Cancer
Conditions
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
Trial Timeline
Aug 5, 2021 → Dec 1, 2025
NCT ID
NCT04713514About OSE2101 + Pembrolizumab 25 MG/ML [Keytruda]
OSE2101 + Pembrolizumab 25 MG/ML [Keytruda] is a phase 2 stage product being developed by Merck for Platinum-sensitive Ovarian Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04713514. Target conditions include Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer.
What happened to similar drugs?
0 of 1 similar drugs in Platinum-sensitive Ovarian Cancer were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04713514 | Phase 2 | Active |
Competing Products
4 competing products in Platinum-sensitive Ovarian Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Farletuzumab + Placebo | Eisai | Phase 2 | 35 |
| Ipilimumab | Bristol Myers Squibb | Phase 2 | 35 |
| AK112 low dose + Chemotherapy + Olaparib + AK112 high dose | Akeso | Phase 2 | 42 |
| ZL-2306(nirapairb) + Placebos | Zai Lab | Phase 3 | 30 |